Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 28

Sort by

Sort Order Select

Journal Articles

Cell Adhesion of ALL to Stromal Cells May Mediate CAR T-Cell Resistance: A Novel Escape Mechanism for Immunotherapy

Hye Na Kim, Enzi Jiang, MD PhD, Ruan Yongsheng, MD, Heather Ogana, Nour Abdel-Azim, Justin Le, BS, Annie Luong, Halvard Bonig, MD, Nabil Ahmed, MD, Moghimi Babak, MD, Michael A. Pulsipher, MD, Deepa Bhojwani, MD, Alan S. Wayne, MD, Chintan Parekh, MBBS, Hisham Abdel-Azim, Nora Heisterkamp, Yong-Mi Kim, MD MPH, PhD

Blood (2019) 134 (Supplement_1): 2623.

https://doi.org/10.1182/blood-2019-132131

Published: 2019

Journal Articles

Reduction in Annualized Bleeding and Factor IX Consumption up to 2.5 Years in Adults with Severe or Moderate-Severe Hemophilia B Treated with AMT-060 (AAV5-hFIX) Gene Therapy

Frank Leebeek, K Meijer, MD, Michiel Coppens, MD, Peter Kampmann, MD, Robert Klamroth, Roger Schutgens, MD PhD MSc, Giancarlo Castaman, Erhard Seifried, MD, J Schwaeble, MD, Halvard Bonig, MD, Eileen K Sawyer, PhD, W Miesbach

Blood (2018) 132 (Supplement 1): 3476.

https://doi.org/10.1182/blood-2018-99-109995

Published: 2018

Journal Articles

Children and Adults with Steroid-Refractory Acute Graft-Versus-Host Disease Respond to Treatment with the Mesenchymal Stroma Cell Preparation "MSC-FFM": Treatment Results for 92 Consecutive Patients

Blood (2018) 132 (Supplement 1): 603.

https://doi.org/10.1182/blood-2018-99-110599

Published: 2018

Journal Articles

Results of a Prospective, Multicenter, Phase I/II Clinical Study in Pediatric and Adult Patients Using TCR Alpha/Beta and CD19 Depleted Haploidentical Hematopoietic Stem Cell Grafts Following Reduced-Intensity Conditioning

Blood (2018) 132 (Supplement 1): 604.

https://doi.org/10.1182/blood-2018-99-110124

Published: 2018

Journal Articles

Efficacy and Safety of a Single Dose of Donor Lymphocytes Depleted of Alloreactive T-Cells (ATIR101) Following T-Cell-Depleted Haploidentical HSCT: A Pooled Analysis of Two Phase II Studies

Denis-Claude Roy, MD, Irwin Walker, MBBS, Johan Maertens, MD, Philippe Lewalle, MD, Eduardo Olavarria, MD PhD, Yves Beguin, MD PhD, Dominik Selleslag, MD, Eva-Maria Wagner, MD, Halvard Bonig, MD, Gerard Bos, MD PhD, Stephan Mielke, MD

Blood (2018) 132 (Supplement 1): 120.

https://doi.org/10.1182/blood-2018-99-119086

Published: 2018

Journal Articles

FLT3 Inhibitor Treatment Increases FLT3 Expression That Exposes FLT3-ITD+ AML Blasts to Elimination By FLT3 CAR-T Cells

Hardikkumar Jetani, Irene García-Cadenas, Thomas Nerreter, Ralph Goetz, Jorge Sierra, MD, Halvard Bonig, MD, Markus Sauer, Hermann Einsele, MD, Michael Hudecek, MD

Blood (2018) 132 (Supplement 1): 903.

https://doi.org/10.1182/blood-2018-99-118171

Published: 2018

Journal Articles

Treatment of Patients with Therapy-Refractory Acute GvHD with the Novel MSC Product "MSC-Ffm" Resulted in Excellent Response and Low Mortality: Post-Approval Observational Data from 69 Consecutive Patients

Blood (2017) 130 (Supplement 1): 514.

https://doi.org/10.1182/blood.V130.Suppl_1.514.514

Published: 2017

Journal Articles

CAR T Cell Relapse CD19 Negative ALL Cells Express Integrins and Integrin Blockade Can Prolong Survival In Vivo

Hye Na Kim, Solah Lee, Kristen Fousek, BS, MS, Shuangyue Li, Anne Kim, Junji Watanabe, PhD, Halvard Bonig, MD MA, Nabil Ahmed, MD, Hisham Abdel-Azim, Nora Heisterkamp, PhD, Yong-Mi Kim, MD MPH, PhD

Blood (2017) 130 (Supplement 1): 2601.

https://doi.org/10.1182/blood.V130.Suppl_1.2601.2601

Published: 2017

Journal Articles

Safety and Efficacy of Tcralpha/Beta and CD19 Depleted Haploidentical Stem Cell Transplantation Following Reduced Intensity Conditioning in Children: Results of a Prospective Multicenter Phase I/II Clinical Trial

Peter J. Lang, MD, Paul G. Schlegel, MD, Roland Meisel, MD, Ansgar S. Schulz, MD, Johann Greil, MD, Peter Bader, MD PhD, Sandra Karitzky, PhD, Silke Holtkamp, Christiane Siewert, PhD, Stefanie Pflitsch, Michael Schumm, DVM, Matthias K. Eyrich, MD, Markus Wiesneth, MD, Halvard Bonig, MD MA, Rupert Handgretinger, MD PhD

Blood (2017) 130 (Supplement 1): 214.

https://doi.org/10.1182/blood.V130.Suppl_1.214.214

Published: 2017

Journal Articles

Stable Elevations in FIX Activity and Reductions in Annualized Bleeding Rate over up to 2 Years of Follow-up of Adults with Severe or Moderate-Severe Hemophilia B Treated with AMT-060 (AAV5-hFIX) Gene Therapy

Frank W.G. Leebeek, MD PhD, K Meijer, Michiel Coppens, MD PhD, Peter Kampmann, R Klamroth, Roger Schutgens, MD PhD, Giancarlo Castaman, Erhard Seifried, MD PhD, J Schwaeble, Halvard Bonig, MD MA, Eileen K Sawyer, Wolfgang A. Miesbach, MD PhD

Blood (2017) 130 (Supplement 1): 602.

https://doi.org/10.1182/blood.V130.Suppl_1.602.602

Published: 2017

Journal Articles

Wave-Complex-Dependent Actin Dynamics Controls Hematopoietic Stem Cell Bone Marrow Retention and Orderly Differentiation into Mature Hematopoietic Lineages

Eliza Wiercinska, PhD, David de Gorter, PhD, Eva Danner, Sabine Harenkamp, Andre Gorgens, PhD, Anja Schwiebs, PhD, Theresia Stradal, PhD, Halvard Bonig, MD MA

Blood (2017) 130 (Supplement 1): 2417.

https://doi.org/10.1182/blood.V130.Suppl_1.2417.2417

Published: 2017

Journal Articles

Donor Lymphocytes Depleted of Alloreactive T-Cells (ATIR101) Improve Event-Free Survival (GRFS) and Overall Survival in a T-Cell Depleted Haploidentical HSCT: Phase 2 Trial in Patients with AML and ALL

Denis-Claude Roy, MD, Silvy Lachance, MD, Jean Roy, MD, Irwin Walker, MBBS, Johan Maertens, MD PhD, Jean-Sebastien Delisle, MD PhD, Stephen Ronan Foley, MD, Philippe Lewalle, MDPhD, Eduardo Olavarria, Dominik Selleslag, MD, Manfred Rüdiger, PhD, Jurjen Velthuis, PhD, Lisya Gerez, Jeroen Rovers, MD PhD, Halvard Bonig, MD MA, Stephan Mielke, MD

Blood (2016) 128 (22): 1226.

https://doi.org/10.1182/blood.V128.22.1226.1226

Published: 2016

Journal Articles

TCR-Alpha/Beta and CD19 Depleted Haploidentical Stem Cell Transplantation Following Reduced Intensity Conditioning in Children: First Results of a Prospective Multicenter Phase I/II Clinical Trial

Peter J. Lang, MD, Paul G. Schlegel, MD, Roland Meisel, MD, Ansgar S. Schulz, MD, Johann Greil, MD, Peter Bader, MD, Sandra Karitzky, PhD, Silke Holtkamp, PhD, Christiane Siewert, PhD, Michael Schumm, VMD, Matthias K. Eyrich, MD, Markus Wiesneth, Halvard Bönig, MD, Rupert Handgretinger, MD

Blood (2016) 128 (22): 389.

https://doi.org/10.1182/blood.V128.22.389.389

Published: 2016

Journal Articles

Expansion and Maintenance of Hematopoietic Stem and Progenitor Cells in Course of Long-Term Inhibition of CXCR4/CXCL12 Signaling

Darja Karpova, PhD, Julie Ritchey, Matthew Holt, Darlene Monlish, PhD, Laura G. Schuettpelz, MD PhD, Wei Yang, Jean-Pierre Levesque, PhD, Allison Robyn Pettit, PhD BSc, Michael P. Rettig, PhD, Halvard Bonig, MD MA, John F DiPersio, MD PhD

Blood (2016) 128 (22): 2648.

https://doi.org/10.1182/blood.V128.22.2648.2648

Published: 2016

Journal Articles

Decentralized Manufacture of TCR-Alpha/Beta and CD19 Depleted Haploidentical Stem Cell Grafts for Children within a Multicenter Phase I/II Clinical Trial

Michael Schumm, VMD, Matthias K. Eyrich, MD, Markus Wiesneth, Halvard Bönig, MD, Peter J. Lang, MD, Paul G. Schlegel, MD, Roland Meisel, MD, Ansgar S. Schulz, MD, Johann Greil, MD, Peter Bader, MD, Murat Aktas, Philipp Dresing, PhD, Sandra Karitzky, PhD, Silke Holtkamp, PhD, Rupert Handgretinger, MD

Blood (2016) 128 (22): 2172.

https://doi.org/10.1182/blood.V128.22.2172.2172

Published: 2016

Journal Articles

Donor Lymphocytes Depleted of Alloreactive T-Cells (ATIR101) Reduce Transplant Related Mortality and Improve Overall Survival in Haploidentical HSCT for Patients with AML and ALL, Using an Immunosuppressant-Free Transplant Regimen

Denis-Claude Roy, MD, Silvy Lachance, MD, Jean Roy, MD, Irwin Walker, MBBS, Johan Maertens, MD PhD, Sandra Cohen, MD, Stephen Ronan Foley, MD, Philippe Lewalle, MD PhD, Eduardo Olavarria, MD PhD, Dominik Selleslag, MD, Manfred Rudiger, Jurjen Velthuis, PhD, Karen Reitsma, PhD, Lisya Gerez, Jeroen Rovers, MDPhD, Halvard Bonig, MD MA, Stephan Mielke, MD

Blood (2015) 126 (23): 4391.

https://doi.org/10.1182/blood.V126.23.4391.4391

Published: 2015

Journal Articles

Potent Stem Cell Mobilization with the Novel CXCR4 Antagonist POL6326 - Results of a Phase IIa Dose Escalation Study in Comparison to G-CSF

Darja Karpova, PhD, Susanne Brauninger, MD, Eliza Wiercinska, PhD, Ariane Kraemer, B.Sc., Belinda Stock, Jochen Graff, MD, Christophe Escot, Garry Douglas, PhD, Barbara Romagnoli, PhD, Eric Chevalier, PhD, Klaus Dembowsky, MD PhD, Leon Hooftman, MD, Halvard Bonig, MD MA

Blood (2015) 126 (23): 511.

https://doi.org/10.1182/blood.V126.23.511.511

Published: 2015

Journal Articles

Overcoming Drug Resistance of Pre-B ALL Cells By Targeting Integrin alpha6 Associated Cell-Adhesion Mediated Drug Resistance Using a Novel Antibody, P5G10

EunJi Gang, MDPhD, Yao-Te Hsieh, PhD, Hye Na Kim, Yann Duchartre, PhD, Shishido Stephanie, PhD, Markus Muschen, MD, Elizabeth Wayner, PhD, Nora Heisterkamp, PhD, Halvard Bonig, MD MA, Yong-Mi Kim, MDPhDMPH

Blood (2015) 126 (23): 2525.

https://doi.org/10.1182/blood.V126.23.2525.2525

Published: 2015

Journal Articles

VLA4 Blockade In Acute Myeloid Leukemia

Yao-Te Hsieh, Enzi Jiang, MD, PhD, Jennifer Pham, Hye-Na Kim, Hisham Abdel-Azim, MD, Sajad Khazal, MD, Gesine Bug, MD, PhD, Gabriele Spohn, Ph.D., Halvard Bonig, MD, MA, Yong-Mi Kim, MD, MPH, PhD

Blood (2013) 122 (21): 3944.

https://doi.org/10.1182/blood.V122.21.3944.3944

Published: 2013

Journal Articles

The Small Molecule Inhibitor of VLA4 TBC3486 Sensitizes Resistant ALL to Chemotherapy

Yao-Te Hsieh, Eun Ji Gang, MD, PhD, Halvard Bonig, MD, MA, Ronald J Biediger, PhD, Peter Vanderslice, PhD, Yong-Mi Kim, MD, MPH, PhD

Blood (2012) 120 (21): 1500.

https://doi.org/10.1182/blood.V120.21.1500.1500

Published: 2012

NARROW

Cell Adhesion of ALL to Stromal Cells May Mediate CAR T-Cell Resistance: A Novel Escape Mechanism for Immunotherapy

Reduction in Annualized Bleeding and Factor IX Consumption up to 2.5 Years in Adults with Severe or Moderate-Severe Hemophilia B Treated with AMT-060 (AAV5-hFIX) Gene Therapy

Children and Adults with Steroid-Refractory Acute Graft-Versus-Host Disease Respond to Treatment with the Mesenchymal Stroma Cell Preparation "MSC-FFM": Treatment Results for 92 Consecutive Patients

Results of a Prospective, Multicenter, Phase I/II Clinical Study in Pediatric and Adult Patients Using TCR Alpha/Beta and CD19 Depleted Haploidentical Hematopoietic Stem Cell Grafts Following Reduced-Intensity Conditioning

Efficacy and Safety of a Single Dose of Donor Lymphocytes Depleted of Alloreactive T-Cells (ATIR101) Following T-Cell-Depleted Haploidentical HSCT: A Pooled Analysis of Two Phase II Studies

FLT3 Inhibitor Treatment Increases FLT3 Expression That Exposes FLT3-ITD+ AML Blasts to Elimination By FLT3 CAR-T Cells

Treatment of Patients with Therapy-Refractory Acute GvHD with the Novel MSC Product "MSC-Ffm" Resulted in Excellent Response and Low Mortality: Post-Approval Observational Data from 69 Consecutive Patients

CAR T Cell Relapse CD19 Negative ALL Cells Express Integrins and Integrin Blockade Can Prolong Survival In Vivo

Safety and Efficacy of Tcralpha/Beta and CD19 Depleted Haploidentical Stem Cell Transplantation Following Reduced Intensity Conditioning in Children: Results of a Prospective Multicenter Phase I/II Clinical Trial

Stable Elevations in FIX Activity and Reductions in Annualized Bleeding Rate over up to 2 Years of Follow-up of Adults with Severe or Moderate-Severe Hemophilia B Treated with AMT-060 (AAV5-hFIX) Gene Therapy

Wave-Complex-Dependent Actin Dynamics Controls Hematopoietic Stem Cell Bone Marrow Retention and Orderly Differentiation into Mature Hematopoietic Lineages

Donor Lymphocytes Depleted of Alloreactive T-Cells (ATIR101) Improve Event-Free Survival (GRFS) and Overall Survival in a T-Cell Depleted Haploidentical HSCT: Phase 2 Trial in Patients with AML and ALL

TCR-Alpha/Beta and CD19 Depleted Haploidentical Stem Cell Transplantation Following Reduced Intensity Conditioning in Children: First Results of a Prospective Multicenter Phase I/II Clinical Trial

Expansion and Maintenance of Hematopoietic Stem and Progenitor Cells in Course of Long-Term Inhibition of CXCR4/CXCL12 Signaling

Decentralized Manufacture of TCR-Alpha/Beta and CD19 Depleted Haploidentical Stem Cell Grafts for Children within a Multicenter Phase I/II Clinical Trial

Donor Lymphocytes Depleted of Alloreactive T-Cells (ATIR101) Reduce Transplant Related Mortality and Improve Overall Survival in Haploidentical HSCT for Patients with AML and ALL, Using an Immunosuppressant-Free Transplant Regimen

Potent Stem Cell Mobilization with the Novel CXCR4 Antagonist POL6326 - Results of a Phase IIa Dose Escalation Study in Comparison to G-CSF

Overcoming Drug Resistance of Pre-B ALL Cells By Targeting Integrin alpha6 Associated Cell-Adhesion Mediated Drug Resistance Using a Novel Antibody, P5G10

VLA4 Blockade In Acute Myeloid Leukemia

The Small Molecule Inhibitor of VLA4 TBC3486 Sensitizes Resistant ALL to Chemotherapy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only